The IPO market stayed busy this past week, with 11 IPOs raising $3.0 billion. The week’s IPOs were joined by 24 SPACs that raised $8.4 billion. New filers continued to fill the IPO pipeline, with 8 IPOs and 46 SPACs submitting initial filings. ...read more
Instil Bio, an early stage biotech developing immune cell therapies for cancer, raised $320 million by offering 16 million shares at $20, the high end of the upwardly revised range of $19 to $20. The company had originally planned to offer 13.9 million...read more
Instil Bio, an early stage biotech developing immune cell therapies for cancer, raised the proposed deal size for its upcoming IPO on Thursday. The Dallas, TX-based company now plans to raise $312 million by offering 16 million shares at a price range of...read more
Instil Bio, an early stage biotech developing cell therapies for cancer, announced terms for its IPO on Monday. The Dallas, TX-based company plans to raise $250 million by offering 13.9 million shares at a price range of $17 to $19. At the midpoint of the...read more
US IPO Weekly Recap: The IPO market heats up in an 11 IPO week
The IPO market stayed busy this past week, with 11 IPOs raising $3.0 billion. The week’s IPOs were joined by 24 SPACs that raised $8.4 billion. New filers continued to fill the IPO pipeline, with 8 IPOs and 46 SPACs submitting initial filings. ...read more
Cancer biotech Instil Bio prices IPO at $20, the high end of the upwardly revised range
Instil Bio, an early stage biotech developing immune cell therapies for cancer, raised $320 million by offering 16 million shares at $20, the high end of the upwardly revised range of $19 to $20. The company had originally planned to offer 13.9 million...read more
Cancer biotech Instil Bio raises deal size by 25% ahead of $312 million IPO
Instil Bio, an early stage biotech developing immune cell therapies for cancer, raised the proposed deal size for its upcoming IPO on Thursday. The Dallas, TX-based company now plans to raise $312 million by offering 16 million shares at a price range of...read more
Cancer biotech Instil Bio sets terms for $250 million IPO
Instil Bio, an early stage biotech developing cell therapies for cancer, announced terms for its IPO on Monday. The Dallas, TX-based company plans to raise $250 million by offering 13.9 million shares at a price range of $17 to $19. At the midpoint of the...read more